Metformin: taking away the candy for cancer?
Explore this paper's citation graph
Summary
The role of diabetes mellitus type 2 and insulin resistance in carcinogenesis, the preclinical rationale and potential mechanisms of met formin's anti-cancer effect and the current and future clinical developments of metformin as a novel anti- cancer drug are discussed.
- Type
- review
- Published
- 2010-09-01
- Cited by
- 400
- References
- 93
- OpenAlex
- https://openalex.org/W2011735982
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:42788419
Keywords
Metformin, Medicine, Insulin resistance, Cancer, AMPK
References
- Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis.
- Abnormal insulin-receptor down regulation and dissociation of down regulation from insulin biological action in cultured human tumor cells.
- Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis.
- Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells
- Incorporating the antidiabetic drug metformin in HER2-positive breast cancer treated with neo-adjuvant chemotherapy and trastuzumab: an ongoing clinical-translational research experience at the Catalan Institute of Oncology.
- Long-term All-Cause Mortality in Cancer Patients With Preexisting Diabetes Mellitus
- Effects of combined recombinant insulin-like growth factor (IGF)-I and IGF binding protein-3 in type 2 diabetic patients on glycemic control and distribution of IGF-I and IGF-II among serum binding protein complexes.
- The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells
- Diabetes mellitus and risk of prostate cancer: a meta-analysis
- PI3K/Akt/mTOR pathway as a target for cancer therapy
- Insulin and its receptor: structure, function and evolution.
- Increased Cancer-Related Mortality for Patients With Type 2 Diabetes Who Use Sulfonylureas or Insulin
- Insulin regulation of human hepatic growth hormone receptors: divergent effects on biosynthesis and surface translocation.
- Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERα negative MDA-MB-435 breast cancer model
- AMP-Activated Protein Kinase in Metabolic Control and Insulin Signaling
- Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro
- The LKB1 tumor suppressor negatively regulates mTOR signaling.
- In vitro metformin anti-neoplastic activity in epithelial ovarian cancer.
- Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action.
- Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3
Cited by
- Association of diabetes mellitus and metformin use with oncological outcomes of patients with non‐muscle‐invasive bladder cancer
- The effect of metformin treatment in vivo on acute and long-term energy metabolism and progesterone production in vitro by granulosa cells from women with polycystic ovary syndrome
- Manipulation du métabolisme énergétique dans les leucémies aiguës myéloïdes : mitochondrie, apoptose et mécanisme d'action de la metformine
- Antidiabetic pharmacology: a link between metabolic syndrome and neuro-oncology?
- Insulin-resistant conditions: A favorable milieu for aggressive drug-resistant malignancies.
- The role of insulin and IGF2 signalling on metabolic pathways in prostate cancer progression
- Clinical potential of the mTOR effectors S6K1, S6K2 and 4EBP1 in breast cancer
- Quantifying the associations between diabetes mellitus, glycated haemoglobin and incidence of and mortality from cancer: analysis of longitudinal data from England and Scotland linked to Cancer Registry and mortality data
- Drug safety advances from ICPE 2010
- Can the therapeutic effects of temozolomide be potentiated by stimulating AMP‐activated protein kinase with olanzepine and metformin?
- A new compartmental method for the analysis of liver FDG kinetics in small animal models
- New perspective for an old antidiabetic drug: metformin as anticancer agent.
- Targeting the mTOR signalling pathway for prevention and therapy of tuberous sclerosis in mouse models
- Metformin for Primary Colorectal Cancer Prevention in Diabetic Patients: A Case-Control Study in a US Population
- The Role of Aspirin, Vitamin D, Exercise, Diet, Statins, and Metformin in the Prevention and Treatment of Colorectal Cancer
- Association between metabolic syndrome, obesity, diabetes mellitus and oncological outcomes of bladder cancer: A systematic review
- Targeting AKT/mTOR Signaling Pathways During Murine Skin Tumor Promotion and the Impact of Dietary Energy Balance Manipulation
- Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin
- Metformin influences progression in diabetic glioblastoma patients
- Optimierung der Therapie des metastasierten Mammakarzinoms unter besonderer Berücksichtigung des Pi3K/Akt/mTOR-Signaltransduktionswegs
Related papers
- Metformin for Prevention of Type 2 Diabetes
- A Rare Side Effect of Metformin: Metformin-Induced Hepatotoxicity
- Metformin-Induced Mitochondrial Complex I Inhibition: Facts, Uncertainties, and Consequences
- Beneficial effects of metformin on primary cardiomyocytes via activation of adenosine monophosphate-activated protein kinase
- Normoglycemia sensitizes MDA‐MB‐231 breast cancer cells to metformin through an AMPK‐dependent mechanism (LB610)
- Metformin - its potential anti-cancer and anti-aging effects.
- Pharmacokinetic-Pharmacodynamic Modeling of Metformin for the Treatment of Type II Diabetes Mellitus
- Drug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated
- A study on the relation of serum fasting true insulin level and insulin resistance with serum lipids in patients with type 2 diabetes mellitus